Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.38 |
| ▸ | RXRA | P19793 | 3/20 | 0.35 |
| ▸ | RXRB | P28702 | 3/20 | 0.35 |
| ▸ | RXRG | P48443 | 3/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.35 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.34 |
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | TACR1 | P25103 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1410779 | 1.00 | LMNA (0.41) | LMNAFFAR4FFAR1RXRARXRB | |
| SCHEMBL1410337 | 1.00 | LMNA (0.41) | LMNAFFAR4FFAR1RXRARXRB | |
| SCHEMBL1410366 | 0.92 | FFAR1 (0.47) | LMNAFFAR4FFAR1RXRARXRB | |
| Tromethamine SCHEMBL1410570 | 0.92 | LMNA (0.36) | LMNAFFAR4FFAR1RXRARXRB | |
| SCHEMBL1410504 | 0.88 | RXRA (0.42) | FFAR4FFAR1RXRARXRBRXRG | |
| SCHEMBL1410689 | 0.87 | FFAR4 (0.44) | LMNAFFAR4FFAR1RXRARXRB | |
| SCHEMBL1409539 | 0.87 | FFAR1 (0.47) | FFAR4FFAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1410134 | 0.84 | ALDH1A1 (0.38) | SLC6A2SLC6A4SLC6A3RORC | |
| SCHEMBL1410421 | 0.82 | PTGIR (0.38) | LMNAFFAR4FFAR1RXRARXRB | |
| SCHEMBL12209968 | 0.78 | SLC6A2 (0.58) | SLC6A2SLC6A4SLC6A3HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250241902-A1 | METHODS, COMPOSITIONS AND SYSTEMS FOR EVALUATION OF VISUAL FUNCTION | BELITE BIO INC (US) | 2025-07-31 | — | — | US | claimed |
| CN-120129485-A | Methods, compositions, and systems for assessing visual function | 英属开曼群岛商倍亮生物有限公司 | 2025-06-10 | — | — | CN | claimed |
| EP-4507566-A1 | METHODS, COMPOSITIONS AND SYSTEMS FOR EVALUATION OF VISUAL FUNCTION | Belite Bio, Inc (US) | 2025-02-19 | — | — | EP | claimed |
| US-20240248099-A1 | BIOMARKERS FOR AGE-RELATED MACULAR DEGENERATION | BELITE BIO, LLC | 2024-07-25 | — | — | US | claimed |
| EP-4340701-A1 | BIOMARKERS FOR AGE-RELATED MACULAR DEGENERATION | Belite Bio, LLC (US) | 2024-03-27 | — | — | EP | claimed |
| CN-117440774-A | Biomarkers of age-related macular degeneration | 倍亮生物有限责任公司 | 2024-01-23 | — | — | CN | claimed |
| WO-2023200766-A1 | METHODS, COMPOSITIONS AND SYSTEMS FOR EVALUATION OF VISUAL FUNCTION | BELITE BIO, INC (US) | 2023-10-19 | — | — | WO | claimed |
| WO-2022246238-A1 | BIOMARKERS FOR AGE-RELATED MACULAR DEGENERATION | BELITE BIO, LLC (US) | 2022-11-24 | — | — | WO | claimed |
| EP-2295406-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2014-04-23 | — | — | EP | claimed |
| US-8338622-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-12-25 | — | — | US | claimed |
| US-20110251187-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-10-13 | — | — | US | claimed |
| EP-2295406-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-03-16 | — | — | EP | claimed |
| US-20250241902-A1 | METHODS, COMPOSITIONS AND SYSTEMS FOR EVALUATION OF VISUAL FUNCTION | BELITE BIO INC (US) | 2025-07-31 | — | — | US | disclosed |
| CN-120129485-A | Methods, compositions, and systems for assessing visual function | 英属开曼群岛商倍亮生物有限公司 | 2025-06-10 | — | — | CN | disclosed |
| EP-4507566-A1 | METHODS, COMPOSITIONS AND SYSTEMS FOR EVALUATION OF VISUAL FUNCTION | Belite Bio, Inc (US) | 2025-02-19 | — | — | EP | disclosed |
| US-20240248099-A1 | BIOMARKERS FOR AGE-RELATED MACULAR DEGENERATION | BELITE BIO, LLC | 2024-07-25 | — | — | US | disclosed |
| US-20110251187-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-10-13 | — | — | US | disclosed |
| US-20110251187-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-10-13 | — | — | US | disclosed |
| US-20110251187-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-10-13 | — | — | US | disclosed |
| EP-2295406-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250241902-A1 | METHODS, COMPOSITIONS AND SYSTEMS FOR EVALUATION OF VISUAL FUNCTION | PDE6C, SERPINA6, PDE6H | LMNA 2480/4885FFAR4 1891/4885FFAR1 2722/4885 |
| US-20240248099-A1 | BIOMARKERS FOR AGE-RELATED MACULAR DEGENERATION | AGER, RBP4, RBP1 | LMNA 1007/4885FFAR4 3691/4885FFAR1 3653/4885 |
| US-20110251187-A1 | HETEROCYCLIC COMPOUND | NES, BMI1, DOT1L | LMNA 2590/4885FFAR4 4589/4885FFAR1 4753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.